| 0.832 | 0.003 | 0.832 | 5 Hydroxytryptamine release stimulant | | |
| 0.588 | 0.005 | 0.588 | 5 Hydroxytryptamine 2 antagonist | | |
| 0.574 | 0.004 | 0.574 | 5 Hydroxytryptamine uptake inhibitor | | |
| 0.539 | 0.01 | 0.539 | Anticonvulsant | | |
| 0.511 | 0.005 | 0.511 | 5 Hydroxytryptamine 2A antagonist | | |
| 0.518 | 0.034 | 0.518 | Antiobesity | | |
| 0.441 | 0.003 | 0.441 | Dopamine uptake inhibitor | | |
| 0.489 | 0.064 | 0.489 | Caspase 9 stimulant | | |
| 0.405 | 0.027 | 0.405 | HERG channel blocker | | |
| 0.385 | 0.012 | 0.385 | 5 Hydroxytryptamine antagonist | | |
| 0.366 | 0.004 | 0.366 | Adrenaline uptake inhibitor | | |
| 0.336 | 0.011 | 0.336 | Acetylcholine antagonist | | |
| 0.356 | 0.035 | 0.356 | Potassium channel (Voltage-sensitive) blocker | | |
| 0.332 | 0.012 | 0.332 | Cholinergic antagonist | | |
| 0.299 | 0.019 | 0.299 | Cholinergic | | |
| 0.288 | 0.016 | 0.288 | Antipruritic | | |
| 0.279 | 0.009 | 0.279 | Alpha 2 adrenoreceptor antagonist | | |
| 0.308 | 0.041 | 0.308 | 5 Hydroxytryptamine uptake stimulant | | |
| 0.281 | 0.017 | 0.281 | Alpha adrenoreceptor antagonist | | |
| 0.271 | 0.013 | 0.271 | Calcium channel blocker | | |
| 0.261 | 0.004 | 0.261 | Myeloperoxidase inhibitor | | |
| 0.258 | 0.01 | 0.258 | 5 Hydroxytryptamine agonist | | |
| 0.264 | 0.017 | 0.264 | 5 Hydroxytryptamine 2B antagonist | | |
| 0.241 | 0.004 | 0.241 | 5 Hydroxytryptamine 2A agonist | | |
| 0.257 | 0.023 | 0.257 | Acetylcholine M1 receptor antagonist | | |
| 0.237 | 0.004 | 0.237 | 5 Hydroxytryptamine 2C agonist | | |
| 0.243 | 0.015 | 0.243 | Acetylcholine muscarinic antagonist | | |
| 0.243 | 0.019 | 0.243 | 5 Hydroxytryptamine 3E antagonist | | |
| 0.227 | 0.004 | 0.227 | 5 Hydroxytryptamine 2 agonist | | |
| 0.225 | 0.004 | 0.225 | Dopamine transporter inhibitor | | |
| 0.233 | 0.016 | 0.233 | Dopamine antagonist | | |
| 0.235 | 0.019 | 0.235 | Sodium channel (voltage-gated) blocker | | |
| 0.293 | 0.078 | 0.293 | Nootropic | | |
| 0.267 | 0.056 | 0.267 | 5 Hydroxytryptamine 1E antagonist | | |
| 0.217 | 0.015 | 0.217 | Dopamine D2 antagonist | | |
| 0.213 | 0.012 | 0.213 | Alpha 2a adrenoreceptor antagonist | | |
| 0.204 | 0.006 | 0.204 | Acetylcholine M4 receptor antagonist | | |
| 0.279 | 0.09 | 0.279 | Caspase 3 stimulant | | |
| 0.193 | 0.015 | 0.193 | 5 Hydroxytryptamine 1A antagonist | | |
| 0.186 | 0.01 | 0.186 | Inducible nitric-oxide synthase inhibitor | | |
| 0.177 | 0.003 | 0.177 | 5 Hydroxytryptamine 2B agonist | | |
| 0.178 | 0.005 | 0.178 | Nicotinic alpha4beta2 receptor antagonist | | |
| 0.182 | 0.01 | 0.182 | Acetylcholine nicotinic agonist | | |
| 0.192 | 0.022 | 0.192 | Alpha 1 adrenoreceptor antagonist | | |
| 0.183 | 0.018 | 0.183 | 5 Hydroxytryptamine 1 antagonist | | |
| 0.172 | 0.012 | 0.172 | CDC-like kinase 3 inhibitor | | |
| 0.186 | 0.027 | 0.186 | Alpha 2b adrenoreceptor antagonist | | |
| 0.177 | 0.019 | 0.177 | Acetylcholine agonist | | |
| 0.193 | 0.035 | 0.193 | Sodium channel blocker | | |
| 0.163 | 0.006 | 0.163 | Acetylcholine M5 receptor antagonist | | |
| 0.191 | 0.041 | 0.191 | CDC-like kinase 1 inhibitor | | |
| 0.171 | 0.02 | 0.171 | Alpha 1a adrenoreceptor antagonist | | |
| 0.219 | 0.07 | 0.219 | Psychostimulant | | |
| 0.152 | 0.006 | 0.152 | Melanin-concentrating hormone receptor 1 antagonist | | |
| 0.187 | 0.045 | 0.187 | MAO inhibitor | | |
| 0.162 | 0.027 | 0.162 | Alpha 2c adrenoreceptor antagonist | | |
| 0.143 | 0.011 | 0.143 | Calcium channel L-type blocker | | |
| 0.146 | 0.015 | 0.146 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | | |
| 0.141 | 0.012 | 0.141 | Acetylcholine M3 receptor antagonist | | |
| 0.2 | 0.076 | 0.2 | Neurotrophic factor enhancer | | |
| 0.253 | 0.132 | 0.253 | Vasodilator, coronary | | |
| 0.125 | 0.004 | 0.125 | Purinergic P2X4 antagonist | | |
| 0.144 | 0.024 | 0.144 | Calcium antagonist | | |
| 0.143 | 0.026 | 0.143 | Nitric-oxide synthase inhibitor | | |
| 0.16 | 0.046 | 0.16 | Sphingosine 1-phosphate receptor 5 antagonist | | |
| 0.159 | 0.045 | 0.159 | Topoisomerase II inhibitor | | |
| 0.137 | 0.024 | 0.137 | Acetylcholine nicotinic antagonist | | |
| 0.211 | 0.099 | 0.211 | Tumour necrosis factor alpha release inhibitor | | |
| 0.126 | 0.016 | 0.126 | Neuronal nicotinic receptor antagonist | | |
| 0.13 | 0.02 | 0.13 | Dopamine D4 antagonist | | |
| 0.146 | 0.038 | 0.146 | MAO B inhibitor | | |
| 0.143 | 0.041 | 0.143 | Papain-like protease (SARS coronavirus) inhibitor | | |
| 0.109 | 0.011 | 0.109 | Nicotinic neuronal receptor agonist | | |
| 0.177 | 0.082 | 0.177 | P-glycoprotein inhibitor | | |
| 0.108 | 0.02 | 0.108 | Nav1.7 sodium channel blocker | | |
| 0.116 | 0.029 | 0.116 | Phosphodiesterase 6D inhibitor | | |
| 0.095 | 0.009 | 0.095 | Nicotinic alpha3beta2 receptor antagonist | | |
| 0.26 | 0.174 | 0.26 | Analgesic | | |
| 0.172 | 0.087 | 0.172 | Hepatoprotectant | | |
| 0.095 | 0.01 | 0.095 | Nicotinic receptor alpha3 subunit antagonist | | |
| 0.096 | 0.014 | 0.096 | I kappa B kinase 2 inhibitor | | |
| 0.13 | 0.05 | 0.13 | Topoisomerase I inhibitor | | |
| 0.128 | 0.048 | 0.128 | Calcium channel (voltage-sensitive) blocker | | |
| 0.102 | 0.024 | 0.102 | Dopamine D1 antagonist | | |
| 0.182 | 0.105 | 0.182 | Potassium channel blocker | | |
| 0.139 | 0.063 | 0.139 | Acetylcholinesterase inhibitor | | |
| 0.172 | 0.098 | 0.172 | I kappa B kinase epsilon inhibitor | | |
| 0.119 | 0.046 | 0.119 | DOPA decarboxylase inhibitor | | |
| 0.11 | 0.039 | 0.11 | Acetylcholine M3 receptor agonist | | |
| 0.105 | 0.035 | 0.105 | I kappa B kinase inhibitor | | |
| 0.115 | 0.047 | 0.115 | Antiadrenergic | | |
| 0.113 | 0.047 | 0.113 | Adrenaline antagonist | | |
| 0.079 | 0.013 | 0.079 | Nicotinic receptor alpha4 subunit antagonist | | |
| 0.086 | 0.026 | 0.086 | Acetylcholine M2 receptor antagonist | | |
| 0.216 | 0.158 | 0.216 | Vasodilator, peripheral | | |
| 0.078 | 0.025 | 0.078 | 5 Hydroxytryptamine 5A antagonist | | |
| 0.07 | 0.019 | 0.07 | Acetylcholine M2 receptor agonist | | |
| 0.078 | 0.028 | 0.078 | 5 Hydroxytryptamine 3 agonist | | |
| 0.106 | 0.06 | 0.106 | MAO A inhibitor | | |
| 0.05 | 0.005 | 0.05 | Nicotinic alpha4beta2 receptor agonist | | |
| 0.08 | 0.035 | 0.08 | Acetylcholine M5 receptor agonist | | |
| 0.098 | 0.053 | 0.098 | Toll-Like receptor 3 antagonist | | |
| 0.074 | 0.029 | 0.074 | Protease activated receptor antagonist | | |
| 0.113 | 0.068 | 0.113 | Sphingosine 1-phosphate receptor 2 agonist | | |
| 0.14 | 0.097 | 0.14 | Melanin inhibitor | | |
| 0.136 | 0.094 | 0.136 | MAP kinase kinase 4 inhibitor | | |
| 0.11 | 0.068 | 0.11 | Nav1.5 sodium channel blocker | | |
| 0.065 | 0.027 | 0.065 | Nicotinic alpha7 receptor agonist | | |
| 0.074 | 0.035 | 0.074 | Dopamine D3 antagonist | | |
| 0.067 | 0.029 | 0.067 | 5 Hydroxytryptamine 5 antagonist | | |
| 0.075 | 0.04 | 0.075 | Dopamine agonist | | |
| 0.08 | 0.046 | 0.08 | Alpha 1b adrenoreceptor antagonist | | |
| 0.06 | 0.028 | 0.06 | Lysine-specific demethylase 1A inhibitor | | |
| 0.051 | 0.019 | 0.051 | GABA B receptor antagonist | | |
| 0.071 | 0.04 | 0.071 | Glutamate (mGluR7) antagonist | | |
| 0.088 | 0.057 | 0.088 | Antineoplastic alkaloid | | |
| 0.06 | 0.029 | 0.06 | Nicotinic receptor alpha7 subunit antagonist | | |
| 0.083 | 0.054 | 0.083 | Phosphodiesterase 11A inhibitor | | |
| 0.083 | 0.054 | 0.083 | Phosphodiesterase XI inhibitor | | |
| 0.108 | 0.08 | 0.108 | Interleukin 8 antagonist | | |
| 0.072 | 0.045 | 0.072 | Toll-Like receptor 7 antagonist | | |
| 0.04 | 0.013 | 0.04 | Endothelin receptor antagonist | | |
| 0.045 | 0.02 | 0.045 | GABA uptake inhibitor | | |
| 0.179 | 0.154 | 0.179 | DNA synthesis inhibitor | | |
| 0.033 | 0.008 | 0.033 | Endothelin B receptor antagonist | | |
| 0.139 | 0.114 | 0.139 | Tumour necrosis factor antagonist | | |
| 0.031 | 0.006 | 0.031 | Imidazoline I1 receptor antagonist | | |
| 0.083 | 0.059 | 0.083 | 5 Hydroxytryptamine 2C antagonist | | |
| 0.126 | 0.104 | 0.126 | NOS3 expression enhancer | | |
| 0.067 | 0.052 | 0.067 | 5 Hydroxytryptamine 1F antagonist | | |
| 0.07 | 0.057 | 0.07 | MAP-kinase-activated kinase 2 inhibitor | | |
| 0.055 | 0.044 | 0.055 | Alpha 1d adrenoreceptor antagonist | | |
| 0.023 | 0.013 | 0.023 | Endothelin A receptor antagonist | | |
| 0.044 | 0.034 | 0.044 | Mannosidase inhibitor | | |
| 0.076 | 0.068 | 0.076 | MAP-kinase-activated kinase inhibitor | | |
| 0.065 | 0.057 | 0.065 | Phosphodiesterase V inhibitor | | |
| 0.147 | 0.139 | 0.147 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | | |
| 0.017 | 0.01 | 0.017 | Nicotinic alpha4 receptor agonist | | |
| 0.123 | 0.117 | 0.123 | Neuropeptide Y1 antagonist | | |
| 0.235 | 0.23 | 0.235 | Cyclophilin D inhibitor | | |
| 0.039 | 0.033 | 0.039 | Dopamine D5 antagonist | | |
| 0.014 | 0.009 | 0.014 | Integrin beta6 antagonist | | |
| 0.011 | 0.007 | 0.011 | Imidazoline I2 receptor antagonist | | |
| 0.076 | 0.072 | 0.076 | GABA A receptor agonist | | |